Company profile for MavriX Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MavriX Bio, launched in 2024 through FAST’s AS²Bio accelerator, is a biotechnology company focused exclusively on Angelman syndrome. Built on pioneering research from Dr. Jim Wilson’s lab at the University of Pennsylvania (now GEMMABio), MavriX aims to advance the first investigational gene replacement therapy for this rare neurogenetic disorder. With strong leadership and strategic guidance from AS²Bio, MavriX is commit...
MavriX Bio, launched in 2024 through FAST’s AS²Bio accelerator, is a biotechnology company focused exclusively on Angelman syndrome. Built on pioneering research from Dr. Jim Wilson’s lab at the University of Pennsylvania (now GEMMABio), MavriX aims to advance the first investigational gene replacement therapy for this rare neurogenetic disorder. With strong leadership and strategic guidance from AS²Bio, MavriX is committed to translating scientific innovation into meaningful clinical progress.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1875 South Grant Street · Suite 700 · San Mateo
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/mavrix-bio-announces-first-patient-dosed-in-ascend-as-trial-of-mvx-220-investigational-gene-therapy-for-angelman-syndrome-302607143.html

PR NEWSWIRE
06 Nov 2025

https://www.prnewswire.com/news-releases/mavrix-bio-receives-fda-fast-track-designation-for-mvx-220-for-treatment-of-angelman-syndrome-302562593.html

PR NEWSWIRE
22 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty